secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akoya Biosciences, Inc. (—)
CIK:        0001711933
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001558370-24-007957
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akoya Q1 revenue falls 14% to $18.4M; cuts FY2024 revenue guidance to $104-$112M
--------------------------------------------------------------------------------

- Revenue $18.4M, down 14% YoY; GAAP operating loss $21.6M (non-GAAP $15.2M).
- GAAP gross margin 46% (57% non-GAAP adjusted) from legacy instrument write-off.
- Installed base up 22% to 1,213; 1,307 publications +52% YoY.
- Cash $61.6M; reaffirms target of operating cash flow breakeven by year-end 2024.
- Cites capex pressure, deferred pharma lab revenue, and reagent fulfillment delays.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711933/000155837024007957/0001558370-24-007957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711933/000155837024007957/akya-20240513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer